The oncogene v-eyk was first isolated from an acute avian retrovirus, RPL30 (38) . It encodes a transmembrane receptortype tyrosine kinase, p69 gp37v-Eyk , in which the intracellular region of the putative receptor tyrosine kinase (RTK) is fused to the viral gp37 glycoprotein, leading to dimerization and activation of v-Eyk (38) . The chicken proto-oncogene c-eyk, from which v-eyk is derived, codes for an RTK with a distinct extracellular region, containing two immunoglobulin-like domains and two fibronectin type III-like repeats (37) . Based on its extracellular structure and the kinase domain sequence, c-Eyk is classified in the same subfamily of tyrosine kinases as Axl/Ark/UFO (36, 49 ; reviewed in reference 67). In addition to Axl/Ark/UFO, members of this subfamily include Sky/Rse/Tif/ Brt/Tyro3 (24, 40, 43, 51) , Rek (4) , and Mer (31) , the last of which is the closest mammalian homologue of c-Eyk. Members of this subfamily of RTKs are expressed in a variety of tissues and cell types: Tyro3 and Rek in different regions of the brain (24, 43, 51) , Tyro3 in ovaries and testes (14, 45) , Mer in monocytes and bone marrow cells (31) , Axl in cell types of mesodermal origin such as thymic stromal cells (20, 53) , and c-Eyk in adult spleen (37) . Several of these RTKs are expressed during embryogenesis in different tissues (30, 37, 50) . The ligands for these RTKs were identified as the anticoagulation factor protein S and the growth arrest-specific gene product Gas6 (47, 63, 68) . The results of several studies addressing the physiological functions of these RTK-ligand systems have indicated roles in the growth and survival of cells (2, 28, 41) and the adhesion and migration (1, 23) of cells. In several cases, members of this subfamily have been implicated in transformation and tumor formation of a variety of cells by overexpression or constitutive activation of the RTK (36, 38, 54) . v-Eyk transformation by infection with the RPL30 virus induces chicken erythroblastosis, fibrosarcomas, endotheliomas, visceral lymphomatosis, and hemorrhage (21) .
We reported that chimeric forms of Eyk that are constitutively dimerized and activated can transform fibroblasts in vitro (74) without significant stimulation of the Ras/ERK (extracellular signal-regulated kinase) pathway which is characteristic for transformation by many oncogenes (60) . In contrast, Eyk strongly stimulated molecules of the Jak (Janus kinase)/STAT (signal transducers and activators of transcription) pathway, namely, Stat1, Stat3, and Jak1 (74) . However, most of the activation of STATs was assessed in COS cells, and transformation frequencies of Stat1 and Stat3 activation were not compared quantitatively.
Activation of the Jak/STAT pathway by cytokine receptor activation is well established (reviewed in references 16, 34, and 59) . Activation of Stat3 by treatment of cells with interleukin 6 (IL-6), a ligand for the gp130 receptor, and activation of Stat1 by treatment with interferons have been well characterized. Stat3 has been implicated in proliferation of cells (13, 25) , whereas Stat1 activation correlates more with immune responses and growth arrest of cells (8, 12) . These notions are supported by the phenotypes of mice harboring targeted disruptions of Stat1 or Stat3. Stat1 Ϫ/Ϫ mice are viable and show severe deficiencies in acute response to infections by a variety of pathogens (19, 46) , whereas Stat3 Ϫ/Ϫ mice die very early in embryonal development, suggesting a possible function for Stat3 activity in the proliferation of cells (64) . The activation of various STAT factors by oncogenes and RTKs has been demonstrated in a growing number of cases, e.g., v-Src (73), v-Abl (15), Bcr-Abl (35), v-Fps and c-Fes (26, 48) , the epidermal growth factor (EGF) receptor (55, 56) , v-Eyk and c-Eyk (74), the hepatocyte growth factor/scatter factor receptor c-Met (5), v-Sis, a ligand activating the platelet-derived growth factorreceptor, and polyomavirus middle-T antigen (26) . Recently, we and others have shown that in the case of v-Src, the activation of Stat3 is required for transformation (7, 66) .
In our initial study (74) , transient-transfection data for activated Eyk molecules in COS cells and the fact that a dominant negative Stat1, Stat1␤, had a negative effect on transformation efficiency suggested that the activation of Stat1 may have been primarily responsible for transformation. In this study, we examined more extensively and quantitatively the importance of Stat1 and Stat3 activation in the transformation of rat 3Y1 fibroblasts by constitutively active c-Eyk and v-Eyk. The constitutively active receptor containing the intracellular portion of the v-Eyk molecule induced strong activation of Stat3, but not of Stat1, and resulted in a higher transformation efficiency. A single amino acid residue (glutamine 936) in the COOH-terminal tail of v-Eyk was found to be responsible for constitutive Stat3 activation and to be required for transformation. The transforming ability of c-Eyk could be converted to that of v-Eyk by changing this single residue from leucine to glutamine. Finally, we conclude from modification in another tyrosine residue in the intracellular domain of the Eyk molecules that Stat3 activation alone is not sufficient for transformation.
ERK assay, Western blotting, and immunoprecipitation), cytoplasmic and nuclear extracts (74) (EMSA and related Western blot analyses), or luciferase extracts (3) or subjected to transformation assays 24 h later.
EMSA was carried out with 2 g of nuclear extract from nontransfected ( Fig.  1) or transfected ( Fig. 3 to 5) cells as described previously (74) , using 32 P-labeled oligonucleotide M67. Western blotting of the resultant cytoplasmic extracts (20 g) as a measure of expression of certain proteins was carried out in parallel according to standard methods (58) and instructions provided by the manufacturer of the immunodetection system.
Luciferase reporter assays with 10 g of extract were performed as described elsewhere (3) . Results were plotted as means Ϯ standard deviations (SD) of experiments performed in duplicate.
Immunoprecipitations were done with various amounts of whole-cell extracts with the different antibodies. Briefly, for each precipitation, 1 g of the antibody was incubated with 20 l of GammaBind G-Sepharose on a rocker table at 4°C for 2 h. The antibody fraction bound to Sepharose was transferred to 200 g of whole-cell extracts (adjusted to 1 mg of total protein/ml) and incubated overnight as described above. The next day, the Sepharose beads were washed four times with extraction buffer and the bound proteins were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting as described above.
Whole-cell extracts (100 g/100 l) from cells transfected with pEBG or pEBG/erk1 (expressing GST-ERK1) together with indicated constructs were precipitated with 20 l of glutathione-beads for 1 h. The beads were washed once with extraction buffer and three times with kinase buffer (30 mM HEPES ⅐ NaOH [pH 7.4], 20 mM MgCl 2 , 2 mM MnCl 2 , 1 mM dithiothreitol). The kinase reaction was carried out for 30 min at 30°C in 20 l of kinase buffer supplemented with 5 g of myelin basic protein (MBP), 2 Ci of [␥-
32 P]ATP (3,000 Ci/mmol), and 10 M ATP. The kinase reaction was subjected to SDS-PAGE (8% gel) and electroblotted to polyvinylidene difluoride membranes (Millipore), and the 32 Plabeled MBP was detected by autoradiography.
Transformation assay. Cells transfected with the various constructs were trypsinized, diluted in 7.5 ml of top agar (0.4% Bacto Agar in DMEM-10% FBS), and spread onto 60-mm-diameter plates containing 5 ml of 0.75% bottom agar (0.75% Bacto Agar in DMEM-10% FBS). The number of colonies of cells which were able to grow in the top agar was determined 2 to 3 weeks after plating.
RESULTS
Stable v-Eyk-transformed cells show increased Stat3 DNA binding and STAT-specific transcriptional activation. Constitutively active forms of c-Eyk and v-Eyk activated by dimerization through linking the CD8␣ extracellular domain to the c-Eyk or v-Eyk internal domain are able to transform immortalized 3Y1 fibroblasts in culture. Furthermore, these dimeric receptor molecules when expressed transiently in COS cells are tyrosine phosphorylated and able to activate Stat1, Stat3, and Jak1 (74) .
Full transformation of cells by v-Src is known to require activation of Stat3 (7, 66) . We first compared 3Y1 cells transformed by CD8-c-Eyk and CD8-v-Eyk with v-Src-transformed cells for constitutive activation of STATs by examining Stat1/ 3-specific DNA binding (EMSA) in nuclear extracts. We used a probe (M67 [33] ) that is known to bind both Stat1 homodimers (originally called sis-inducible factor C [SIF C] [69] ) and Stat3 homodimers (SIF A) as well as the Stat1/3 heterodimers (SIF B). As found previously for NIH 3T3 fibroblasts (73), v-Src-transformed 3Y1 cells constitutively activated Stat3 as well as a lesser amount of the Stat1/3 heterodimer (Fig. 1A, upper panel) . CD8-v-Eyk-transformed cells had very strong Stat3 activation, a small amount of the heterodimer, and no detectable activation of Stat1. In CD8-c-Eyk transformed cells, small amounts of all three dimers were observed. The same results were obtained in a number of different transformed 3Y1 cell clones. The nature of these complexes has been confirmed by supershift analyses using Stat1-or Stat3-specific antibodies (data not shown).
The transformed cells were examined for transcriptional activation of a reporter gene construct bearing four copies of the M67 site that is responsive to Stat1 or Stat3 activation. The CD8-v-Eyk-transformed cell line showed a significantly higher activity of the Stat1/3-responsive promoter than the v-Src-transformed cell line, correlating with the large amount of activated Stat3 in these cells. Nontransformed and CD8-cEyk-transformed 3Y1 cell lines did not show a Stat1/3-specific transcriptional response (Fig. 1B) .
As a measure of the transformed phenotype, equal numbers of cells (10 4 ) were plated for colony formation in soft agar. v-Src-transformed cells formed 10 times as many colonies as cells transformed by CD8-v-Eyk. However, CD8-c-Eyk-transformed cells formed only about one-fourth as many colonies as CD8-v-Eyk transformed cells (Fig. 1C) .
Expression of different Eyk constructs induces transformation and increased tyrosine phosphorylation but no activation of ERK1.
To further analyze the ability of CD8-Eyk molecules to induce transformation and to score their relative transformation efficiencies, we transfected a series of constructs into 3Y1 cells and after 3 weeks determined the number of transformed cells leading to colonies in soft agar were ( Fig. 2A) .
The transformation assay clearly showed greater transforming ability by CD8-v-Eyk than by CD8-c-Eyk (99 Ϯ 33 and 9 Ϯ 4, respectively. A kinase-dead CD8-c-Eyk construct (CD8-cEykM) included as a negative control did not lead to the formation of soft agar colonies.
To determine why CD8-c-Eyk and CD8-v-Eyk differ in the ability to induce transformation, we studied the signaling events mediated by these two constructs in transient transfection experiments. The total tyrosine-phosphorylated proteins in CD8-c-Eyk-and CD8-v-Eyk-transfected 3Y1 cells were comparable (Fig. 2B, upper panel) . The asterisks in Fig. 2B indicate phosphorylated proteins, including the expressed CD8-Eyk molecules and their degradation products and three unidentified phosphoproteins.
Activation of the Ras/ERK pathway has been shown for other members of the Axl/Tyro3 subfamily (22, 41) . Results of an ERK1 assay using cells cotransfected with a construct expressing GST-ERK1 and several constructs expressing CD8-Eyk proteins, v-Src, or Ras61L is shown in Fig. 2C . Under the conditions used here, the level of ERK1 activation was not altered by CD8-c-Eyk, CD8-v-Eyk, or the kinase-dead mutant CD8-c-EykM compared to the ERK1 activity level observed in noninduced cells transfected with pMEXneo. However, ERK1 is activated in cells transfected with v-Src, Ras61L, or pMEXneo (treated with EGF). The observed activation of ERK1 by v-Src seems to be due to an increased expression level of ERK1 rather than increased activation based on the expression levels of GST-ERK1 (Fig. 2C, lower panel) . Furthermore, we found no differences in ERK1/2 activation between the nontransformed and CD8-Eyk-transformed 3Y1 cell clones (data not shown).
These results together with the finding of similar levels of kinase activity of the two CD8-Eyk proteins (data not shown) indicated that the differences in transformation efficiency between CD8-c-Eyk and CD8-v-Eyk were not due to their overall ability to phosphorylate cellular proteins, their kinase activity, or their capacity to induce ERK.
Transient expression of Eyk proteins leads to differential DNA binding of Stat3 and Stat1, resulting in activation of a Stat1/3-responsive promoter construct. Since stably transformed CD8-v-Eyk cells exhibited constitutive activation of Stat3, we determined the effects of transient transfection of CD8-c-Eyk and CD8-v-Eyk on Stat1/3-specific DNA binding and Stat1/3-specific transcriptional activation (Fig. 3) . As previously shown in studies using COS cells (74) , CD8-c-Eyk activates Stat1 and some Stat1/3 heterodimer, indicating that Stat3 is activated but to a lesser extent than Stat1. CD8-v-Eyk led to similar activation of Stat1 but much stronger activation of Stat3 compared to CD8-c-Eyk. A mutation in the kinase domain of Eyk in the construct CD8-c-EykM obliterated the activation of Stat1 and Stat3. As shown for v-Src-transformed 3Y1 cells (Fig. 1A, upper panel) , v-Src activates Stat3 preferentially in 3Y1 cells when transiently expressed (Fig. 3A) . The nature of the complexes observed in the EMSA has been confirmed by supershift analyses using Stat1-and Stat3-specific antibodies (data not shown).
Consistent with the greater activation of Stat3 by CD8-vEyk and v-Src than by CD8-c-Eyk, we observed a greater induction of the Stat1/3-responsive promoter construct when it was coexpressed with these molecules: about 200-fold induction by CD8-v-Eyk and v-Src but only 35-fold induction by CD8-c-Eyk (Fig. 3B) .
A YVPQ sequence in the COOH terminus of CD8-v-Eyk is responsible for increased Stat3 activation and increased transformation efficiency. The coding sequences of c-Eyk and v-Eyk differ in several regions (37) . CD8-c-Eyk contains the We first determined that the transmembrane domain of CD8␣ and the 21 intracellular amino acids of c-Eyk are not responsible for the differences in Stat3 activation and transformation (data not shown). We then tested whether the exchange of the COOH termini between CD8-c-Eyk and CD8-v-Eyk influenced the activation of Stat3 and the transformation efficiency. Interestingly, the COOH terminus of CD8-v-Eyk (amino acids 918 to 974) when linked to the NH 2 terminus CD8-c-Eyk could confer Stat3 activation and high transformation capability (data not shown), suggesting that the mutation L936Q is responsible for these abilities. Amino acid 936 is juxtaposed to a potentially phosphorylated tyrosine residue at position 933, corresponding to the sequences Y 933 VPL in CD8-c-Eyk and Y 933 VPQ in CD8-v-Eyk. To test the hypothesis that Y 933 VPQ in CD8-v-Eyk is responsible for Stat3 activation and higher transformation efficiency, we performed site-directed mutagenesis to obtain mutated CD8-Eyk molecules (Fig. 4A) . CD8-c-EykL936Q showed strong activation of Stat3 as tested by DNA binding (Fig. 4B) , STAT-responsive transcription (Fig. 4C) , and increased number of soft agar colonies (Fig. 4D) . CD8-vEykY933F lost the ability to activate Stat3 and showed trans- 6 ) were transfected with 2 g of the indicated constructs and 2 days later transferred to soft agar; colony numbers were determined 3 weeks later. Each column represents the average of two samples, with the positive SD indicated as an error bar (n ϭ 2). The original numbers are indicated beside the columns. (B) 3Y1 fibroblasts were transfected with 15 g of pMEX/neo, pMEX/CD8-c-Eyk (CD8-c-Eyk), or pMEX/CD8-v-Eyk (CD8-v-Eyk). Two days later, whole extracts were prepared and tyrosine-phosphorylated proteins (asterisks in the upper panel) and Eyk protein levels (lower panel) were detected in 20 g of whole extract by Western blotting using a phosphotyrosine-specific antibody or an Eyk-specific antibody, respectively. (C) 3Y1 fibroblasts (0.15 ϫ 10 6 cells) were transfected with 100 ng of pEBG (Ϫ) or pEBG/erk1 (ϩ) together with 500 ng of plasmid expressing the indicated protein. Two days later, the cells were either treated with 50 ng of EGF per ml (ϩEGF) for 10 min or left untreated, and whole-cell extracts were prepared. GST-ERK1 was precipitated by using glutathione-beads, and kinase activity toward MBP was determined (upper panel). GST-ERK1 was detected with a GST-specific antibody (Santa Cruz) (lower panel). In the rightmost lane, one-fifth of the kinase reaction for Ras61L was loaded to avoid overexposure. formation efficiency as low as that observed for CD8-c-Eyk. As mentioned above, CD8-c-Eyk can activate Stat1 and minimally Stat3 (Fig. 3A) , leading to Stat1/3-specific transcriptional activation (Fig. 3B) . To further test the importance of tyrosine 933, we also introduced a Y933F mutation in CD8-c-Eyk. The construct CD8-c-EykY933F did not show any difference from the wild-type CD8-c-Eyk, suggesting that Y933 is important for Stat3 activation only in conjunction with a glutamine in the ϩ3 position. As expected from the results with CD8-c-EykM described above, two kinase-dead constructs, CD8-cEykK609M and CD8-v-EykK609M, neither activated the STAT pathway nor led to transformation of 3Y1 fibroblasts.
As seen in Fig. 4B , the activation of Stat1 remained unchanged in all tested constructs excluding the kinase-dead molecules, suggesting that another region in the CD8-Eyk molecules is responsible for the activation of Stat1 and the residual activation of Stat3. In an attempt to identify this site(s), we mutated the other five tyrosines outside the kinase domain to phenylalanines in both CD8-c-Eyk and CD8-v-Eyk. All of these constructs, each containing a single amino acid substitution, behaved like their wild-type nonmutated counterparts, indicating that none of these tyrosines is required alone for the activation of Stat1 and the residual activation of Stat3 (data not shown). The mutant construct CD8-v-Eyk⌬890 contains a Y862F mutation, followed by 28 nonrelated amino acids and a stop codon at amino acid 890. Interestingly, this construct could still activate Stat1 and Stat1/3-responsive transcription to the same level as CD8-c-Eyk level, although the COOH terminus of CD8-v-Eyk including Y933 responsible for high Stat3 activation is missing (Fig. 4B and C) . The antibody against the COOH terminus of Eyk used in Western blot analyses (Fig.  4B, lower panel) did not recognize this construct. These results indicated that the site(s) responsible for the activation of Stat1 and the residual Stat3 activation is not located in the COOH terminus and is either a tyrosine in the kinase domain or a non-tyrosine-binding site.
A YVNT sequence is required for transformation. Two of the ten Y-to-F mutants that were generated in the CD8-c-Eyk and the CD8-v-Eyk backgrounds to identify the site responsible for Stat1 activation (see above), namely, CD8-c-EykY862F and CD8-v-EykY862F, showed interesting phenotypes. Both constructs were able to activate the STAT pathway similarly to their wild-type counterparts (Fig. 4B and C) but showed a greatly reduced ability to transform 3Y1 fibroblasts (Fig. 4D) . These results indicated that activation of Stat3 by CD8-v-Eyk cooperates with another independent signaling pathway to transform 3Y1 cells in culture. Note that all transfectants analyzed in soft agar assays were also grown on plates containing , and the intracellular domain including the kinase domain (kinase) and tyrosine residues (vertical bars) are shown. Point mutations in four different sites are indicated in the context of wild-type CD8-c-Eyk and CD8-v-Eyk: leucine in CD8-c-Eyk 936 to glutamine and tyrosine 933 to phenylalanine, tyrosine 862 to phenylalanine, and lysine 609 to methionine (kinase dead) in both CD8-Eyk constructs. ⌬890 denotes a COOH-terminal deletion construct of CD8-v-Eyk displaying the Y862F mutation followed by 28 unrelated amino acids (aa) and a stop codon. (B) 3Y1 cells were transfected with 2 g of the indicated construct. Two days after transfection, the cells were harvested and nuclear and cytoplasmic extracts were prepared. EMSA using oligonucleotide M67 as the probe and Western blot analysis for Eyk expression were carried out as described for Fig. 1A . (C) 3Y1 cells were transfected with 100 ng of p4xM67-tk-Luc together without or with 50 ng of the indicated construct. Luciferase activity was determined 2 days later as described for Fig. 1B. (D) 3Y1 cells were transfected with 2 g of the indicated construct. The transformation efficiency was determined in a soft agar assay as described for Fig. 3D. selective medium. G418-resistant clone numbers were comparable between wild-type and mutant receptor constructs, indicating that there is no difference in the apoptosis in cells bearing the various receptors (data not shown).
The YVPQ sequence is required for binding of Stat3 but not of Stat1. The sequence Y 933 VPQ in CD8-v-Eyk fits the determined consensus binding sequence YXPQ in the gp130 receptor for the Stat3 SH2 domain (32) . Therefore, we determined whether Stat3 interacts with CD8-Eyk molecules harboring the Y 933 VPQ sequence. Different mutants of CD8-c-Eyk and CD8-v-Eyk in conjunction with FLAG-tagged Stat1 (Fig. 5A) or Stat3 (Fig. 5B) were transiently expressed in 293T cells. To detect an interaction between CD8-Eyk molecules and the various STAT molecules, we immunoprecipitated the STAT molecules with the FLAG epitope-specific antibody M2 and then determined the levels of CD8-Eyk and Stat1/3 molecules in the immunoprecipitates (Fig. 5) . Expression of CD8-Eyk molecules was determined in whole-cell extracts from the transfected cells (Fig.  5A and B, upper panels) . All CD8-Eyk molecules including the kinase-dead mutants CD8-c-EykK609M and CD8-vEykK609M were able to interact with Stat1 (Fig. 5A) . It is noteworthy that the expression level of the Stat1 molecules is influenced by the coexpression of kinase-active CD8-Eyk molecules.
In a similar experiment using FLAG-tagged Stat3 (Fig. 5B) , interaction between CD8-Eyk and Stat3 was detected only when the CD8-Eyk molecule contained tyrosine 933 and glutamine 936, i.e., in the constructs CD8-c-EykL936Q, wild-type CD8-v-Eyk, and CD8-v-EykY862F. These results show that Stat3 could specifically interact with CD8-Eyk molecules harboring the Y 933 VPQ sequence found originally in CD8-v-Eyk. Stat1 interacted with all CD8-Eyk constructs most likely independent of tyrosine phosphorylation. Thus, the interaction of Stat3 and Stat1 with different CD8-Eyk molecules correlated with the activation of the STAT pathway (Fig. 4B and C) . Eyk molecules could not be detected when FLAG-tagged Stat3 was coexpressed with Eyk molecules which do not activate Stat3 (all CD8-c-Eyk constructs except CD8-c-EykL936Q, CD8-vEykY933F, and CD8-v-EykK609M), indicating that the FLAG antibody did not precipitate Eyk molecules in Fig. 5 unspecifically. The additional bands observed are either Eyk degradation products (Fig. 5A and B, upper and middle panels) , cross-reactivity between the anti-FLAG antibody and the horseradish peroxidase-conjugated secondary anti-rabbit antibody ( Fig. 5A and B, middle panels) , or Stat1 (Fig. 5A, lower  panel) or Stat3 (Fig. 5B, lower panel) degradation products. None of these degradation products seem to be significant for the results presented in this study.
DISCUSSION
We have analyzed the signaling pathways downstream of activated Eyk molecules leading to transformation of 3Y1 fibroblasts and demonstrated the importance of Stat3 activation. Although Stat1 is activated by both Eyk molecules, this activation did not correlate with cellular transformation or with transcriptional activation.
The activation of Stat3 by the RTK CD8-v-Eyk presumably occurs directly after binding of Stat3 via its SH2 domain to a Y 933 VPQ sequence present in v-Eyk and by the subsequent tyrosine phosphorylation of Stat3 (Fig. 4 and 6 ). Similar sequences (YXXQ) have been shown to be important for Stat3 activation by Jak kinases in several cytokine receptors, e.g., the IL-10 receptor (71), the granulocyte colony-stimulating factor receptor (17) , and gp130, the receptor activated after IL-6 treatment (32, 62) . Unlike the cytokine receptors, the Stat3 docking sites for growth factor (e.g., EGF and platelet-derived growth factor) receptors which activate Stat3 had not been clearly defined. Stat3 activation by the hepatocyte growth factor/scatter factor receptor c-Met has been shown to be involved in epithelial tubule formation. A putative sequence for Stat3 binding in c-Met was suggested to be Y 1356 VNV, which also binds several other proteins (5) . Interestingly, a similar sequence, Y 862 VNT, is present in Eyk, but appears not to be responsible for Stat3 activation although it is required for transformation (see below). c-Met also contains a YXXQ sequence, which raises the question of whether a synergistic effect similar to that described here for the transformation by CD8-v-Eyk is responsible for epithelial tubule formation by c-Met. It is noteworthy that v-Src does not contain a YXXQ sequence, suggesting that the activation of Stat3 by v-Src could involve another binding site for Stat3 (11) .
The observed activation of Stat1 by the CD8-Eyk molecules (Fig. 3) does not require the Y 933 VPQ sequence; therefore, Stat1 must bind to some other sites in both c-Eyk and v-Eyk (Fig. 5) . We do not know whether Stat1 activation can have a negative effect on transformation efficiency, since Stat1 activation has been previously implicated in growth arrest of cells (8, 12) . In fact, comparing the transformation efficiencies of CD8-v-Eyk and v-Src (data not shown and Fig. 1 stat1-FLAG together with 1 g of the indicated construct. Two days after transfection, the cells were harvested and whole-cell extracts were prepared. FLAGtagged Stat1 was immunoprecipitated (IP) from 400 g of extract, using the FLAG-specific antibody M2 (␣-FLAG). Whole-cell extracts (WE; upper panel) and immunoprecipitates (middle and lower panels) were analyzed by Western blotting (WB) for expressed or coprecipitated Eyk levels (upper and middle panel) or FLAG-tagged Stat1 levels as described for Wild-type and dominant negative Stat3 molecules have been shown to be efficiently block transformation by v-Src in NIH 3T3 cells (7, 66) . We tried to examine the effect of these molecules and the associated Stat1 molecules on the transformation of 3Y1 cells. Coexpression of CD8-Eyk molecules with wild-type Stat1 or Stat3 greatly increased DNA-binding activity, and coexpression of CD8-Eyk with Stat3 led to increased Stat1/3-specific transcriptional activation (data not shown). Nevertheless, neither Stat1Y-F nor Stat3Y-F molecules (7) had a dominant negative influence on the DNA binding of the endogenous STAT molecules, or transcriptional activation, or on transformation by the CD8-Eyk and the v-Src molecules. All STAT molecules in these assays were expressed to detectable levels. We do not know why these dominant negative molecules are not functional under the conditions used here.
We previously reported that Stat1␤ acted as a suppressor of Eyk transformation in 3Y1 cells. Stat1 and Stat1␤ can form heterodimers with Stat3, and eventually the dominant negative construct Stat1␤ blocks the activation of Stat1 and Stat3 to the same extent and leads to a reduced number of soft agar colonies because of the blockage of Stat3.
The activation of Jak1 has been shown to be important for the activation of STAT molecules. We reported previously that CD8-Eyk molecules can activate Jak1 (74) . The function of this activation for the activation of Stat3 and the transformation remains to be elucidated. Interestingly, Jak1 is also activated in v-Src-transformed fibroblasts, although the importance of this activation for transformation has not been investigated (10) .
We present evidence that maximal transformation frequency by CD8-v-Eyk not only is dependent on Stat3 activation but also requires the activation of another pathway activated through the Y 862 VNT sequence that is present in both CD8-Eyk proteins.
The amino acid sequence following the tyrosine at position 862 is VNT. The asparagine at ϩ2 is highly conserved in the homologous sequence among all members of the Axl/Tyro3 subfamily. A YXNX motif has been reported to be a docking site for the SH2 domain of Grb2 (61) . Grb2 as well as other molecules can bind to this motif in Axl (6) . Since docking of Grb2 to receptors leads to the activation of the Ras/ERK pathway (42) , one might expect activation of this pathway downstream of CD8-Eyk via the Y 862 VNT sequence. Several reports demonstrated the activation of ERK downstream of other members of the Axl subfamily in 32D cells and in NIH 3T3 fibroblasts (22, 41) . The involvement of the activation of the Ras/ERK pathway for the physiological function of these receptors has not been addressed. Although we did not observe activation of ERK1 in 3Y1 cells (Fig. 2C) , we found that in NIH 3T3 cells, CD8-c-Eyk and CD8-v-Eyk are able to modestly activate GST-ERK1, suggesting cell line specific regulation of this pathway (data not shown). However, increased ERK activity does not appear to occur in the transformation of 3Y1 cells by CD8-Eyk. A homologous tyrosine in c-Axl (Y 821 VNM) seems to be involved in the activation of phosphatidylinositol (PI) 3-kinase, S6 kinase and protein kinase B (PKB)/Akt (6, 29), and we reported that the homologous tyrosine in the c-Mer receptor, the closest mammalian homologue of c-Eyk, leads to activation of NF-B (27) . A very recent study shows that this sequence in c-Axl is required for transformation (9) . We are investigating the potential role of these molecules in the signaling events downstream of Y862 in CD8-Eyk.
In conclusion, we propose the following model for the signaling events downstream of CD8-c-Eyk and CD8-v-Eyk leading to the transformation of immortalized 3Y1 fibroblasts (Fig.  6) . Both molecules are able to bind and activate Jak1 (74), Stat1, and minimally Stat3 via a region residing in the kinase domain or the intracellular region N terminal to the kinase domain. The major difference between the cellular form CD8-c-Eyk and the viral form CD-v-Eyk is the strong binding of Stat3 to CD8-v-Eyk via a YVPQ sequence (Fig. 5) , DNA binding, and transcriptional activation (Fig. 3) . A second pathway which appeared to be important for the transformation events by both CD8-Eyk molecules involves Y 862 VNT. This activation seems to be responsible for the transformation events downstream of CD8-c-Eyk since a construct missing this tyrosine is virtually unable to induce transformation. In CD8-v-Eyk, this pathway synergizes with the activation of Stat3, resulting in transformation efficiency 10-fold higher than that of CD8-c-Eyk.
Our model illustrates how two independent signaling pathways cooperate in inducing transformation in 3Y1 fibroblasts. We speculate that the mutation of Y 933 VPL to Y 933 VPQ upon retroviral transduction of the RPL30 virus, harboring v-Eyk, gained a biological advantage by leading to strong activation of Stat3.
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